🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  3. DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

  4. DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s

    Lacuna Pharma Pty Ltd

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  6. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  8. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  10. Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection

    ViiV Healthcare Pty Ltd

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  11. Doxorubicin 2 mg/ml Solution for Injection., Fibromun

    Philogen S.p.A.

    Unresectable or metastatic soft tissue sarcoma

    phase 3 small molecule active

    1 trial

  12. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  13. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  14. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  15. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial

  16. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  17. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  18. EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled pen, EVENITY 105 mg solution for injection in pre-filled pen

    Amgen

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial

  19. EXPAREL 13.3Mg/mL Suspension for Injection

    Pacira Ireland Limited

    Bunion

    phase 3 small molecule terminated

    1 trial

  20. Ebglyss 250 mg solution for injection in pre-filled syringe, Placebo, Ebglyss 250 mg solution for injection in pre-filled pen

    Almirall, S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  21. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  23. Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection

    Janssen-Cilag International N.V.

    Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  24. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen

    Takeda

    Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources